Case Study: Humira Cost Savings Through Biosimilar Access
- Clinical Services International (CSI)
- 2 days ago
- 1 min read
Client: Mid-size biotech conducting multiple clinical trials
Challenge: The client required a large quantity of Humira (adalimumab) for several upcoming studies. High costs and limited availability were putting pressure on study budgets and timelines.
Solution: CSI leveraged its industry insight and direct relationships with the manufacturer to provide access to a high-quality adalimumab biosimilar. This saved the client a staggering 50% on price. By carefully coordinating sourcing and supply, we ensured uninterrupted study timelines while maintaining compliance.
Results:
Cost savings: Thousands of dollars saved with biosimilar adalimumab compared to brand-name Humira.
Timely supply: No delays in trial enrolment or dosing schedules.
Seamless support: Certificates of Analysis (CoAs), first-leg documents and stability data were provided.
Conclusion: By partnering with CSI, the client was able to reduce drug costs significantly without compromising on quality or timelines, demonstrating the value of strategic comparator sourcing for clinical trials.
.png){kind=logo}